Services built for data trust, standards, and AI readiness.
VitalFrame engagements follow a clear three-phase model: Audit → Modernize → Monitor. Scope is tailored to your current state, data sources (EHR / claims / labs / pharmacy), and regulatory context.
1 · Source data
EHR · Claims · Labs · Pharmacy
Fragmented sources with inconsistent coding and unclear definitions.
2 · Data Quality
Profiling + remediation
Quantify risk and prioritize fixes that unblock reporting and AI.
3 · Standardize
OMOP-aligned structure
Reusable patient-level datasets for consistent analytics and cohorts.
4 · Interoperate
FHIR-aligned outputs
Shareable resources for downstream systems, reporting, and exchange.
Phase 1 — Audit
Quantify maturity and data-quality risk; define priorities that unblock reporting and AI.
Phase 2 — Modernize
Remediate high-impact issues and standardize structure and outputs (OMOP, FHIR).
Phase 3 — Monitor
Sustain quality with automated checks, alerts, governance signals, and drift monitoring.
Phase 1 — Audit
Data Audit & Maturity Assessment
Executive clarity + priorities
Data Audit & Maturity Assessment
Establish an objective view of maturity and data-quality risk across your most important sources, with findings tied directly to reporting reliability, compliance, and AI readiness.
Focus areas
- DQ profiling: completeness, validity, conformance, integrity, timeliness
- Standards posture: OMOP structure and FHIR-aligned exchange patterns
- Governance: ownership, definitions, controls, auditability
- AI blockers: missing labels, unit drift, unlinked events, inconsistent coding
Outputs
- Executive-ready scorecards by domain
- Prioritized findings with impact and remediation themes
- Scope-driven roadmap and target-state direction
Phase 2 — Modernize
Data Modernization & AI Readiness
Standardize + enable use cases
Data Modernization & AI Readiness
Remediate the highest-impact issues identified in Phase 1, standardize structure and outputs, and prepare reusable foundations for analytics and AI.
Focus areas
- Remediation: duplicates, broken encounters, invalid codes, temporal consistency
- Normalization: units, reference ranges, coding consistency
- OMOP-aligned datasets for repeatable analytics and cohort building
- FHIR-aligned outputs for sharing insights and exchange
Outcomes
- Analysis-ready datasets and reusable cohorts and features
- Reduced friction for dashboards, reporting, and modeling
- Traceable transformation logic and defensible definitions
Phase 3 — Monitor
Ongoing Data Health Monitoring
Sustain trust over time
Ongoing Data Health Monitoring
Keep quality stable as systems evolve. Automated checks, alerts, and governance signals that prevent degradation from quietly impacting decisions and AI performance.
Focus areas
- Automated DQ checks, alerts, and score trends
- Vocabulary drift and unmapped code detection
- Freshness and operational monitoring across pipelines
- Model and cohort stability signals where applicable
Outcomes
- Reliable reporting and analytics continuity
- Early detection of degradation before it becomes visible
- Audit-ready governance and documented controls
Frequently asked questions
Everything you need to know before starting an engagement. Can’t find what you’re looking for? Email us directly.
About the engagement
What exactly is Phase 1 and what do we get at the end?
Phase 1 is a fixed-scope, fixed-fee data audit lasting 3–6 weeks. We profile your clinical and administrative data, assess your standards posture (OMOP, FHIR), evaluate governance maturity, and identify the specific issues blocking your reporting, compliance, and AI initiatives. At the end you receive executive-ready scorecards by domain, a prioritized findings report tied to business impact, and a phased modernization roadmap. You walk away with a clear, defensible picture of where your data risk actually sits — whether you continue with us or not.
Do you need write access to our systems?
No. Phase 1 is entirely read-only. We work with read-only SQL access, encrypted data extracts over SFTP, or client-run scripts we provide — whichever method your IT and security teams are comfortable with. We never require write access to production systems and we don’t store PHI locally.
Are we committed to Phases 2 and 3 after completing Phase 1?
Not at all. Phase 1 is designed to stand on its own. Many organizations use the findings to guide their internal teams or inform vendor decisions without engaging further. Phases 2 and 3 are driven entirely by what the audit uncovers — we never pre-sell implementation before understanding your reality.
How is VitalFrame different from a traditional IT consulting firm?
Two key differences. First, we are deeply specialized in healthcare data standards — OMOP, FHIR, HL7, clinical vocabularies — not general IT delivery. Second, our model is fixed-scope and outcome-oriented, not time-and-materials. We price clarity and risk reduction, not headcount. You know exactly what you’re getting before we start, and we don’t create unnecessarily long engagements.
Do you sign BAAs and NDAs?
Yes, both. A Business Associate Agreement (BAA) is mandatory before we access any PHI — we can sign yours or provide our own. An NDA is standard for all engagements and is signed before any scope discussions. We also carry professional liability (E&O) and cyber liability insurance, which most healthcare organizations require before onboarding any data vendor.
Standards, data & AI
Do we need both OMOP and FHIR, or just one?
They solve different problems. OMOP prepares your data for analytics and AI — it creates a consistent, patient-level structure that makes reporting, cohort building, and modeling repeatable. FHIR makes that prepared data accessible and shareable with other systems. If your goal is purely internal analytics, OMOP alone may be sufficient. If you need to exchange data with partners, regulators, or downstream applications, FHIR becomes essential. Most mature organizations benefit from both, but we never recommend more than your use case actually justifies.
Can we start building AI models before fixing our data?
Technically yes — but the model will almost certainly underperform or fail in production. The most common causes of AI failure in healthcare are not algorithmic — they are data problems: missingness in key features, inconsistent clinical coding, broken event linkages, and unit drift that quietly corrupts inputs. Building on unvalidated data means you’re amplifying problems you don’t know exist. VitalFrame’s position is simple: data readiness is AI safety.
What types of data do you work with?
We work across the full range of clinical and administrative healthcare data — EHR data (encounters, diagnoses, procedures, medications, labs, vitals), claims and billing data, pharmacy, imaging metadata, and provider and organization master data. For Phase 1 we typically need read-only access to your core clinical and administrative tables. We work with whatever coding systems are in place: ICD-10, CPT, LOINC, RxNorm, SNOMED, and local or custom vocabularies.
How is Phase 1 priced and what drives the cost?
Phase 1 is fixed-fee, ranging from $15,000 to $45,000 depending on the number of data sources, data volume, and complexity of your environment. Pricing scales with data complexity — not headcount, not meeting count, not how much chaos we uncover. Smaller organizations with a single EHR system sit at the lower end; large multi-system environments or government entities sit at the higher end. We confirm scope before proposing anything.
What does ongoing monitoring (Phase 3) actually cover?
Phase 3 is a subscription that keeps your data quality stable after the initial remediation work. It includes automated DQ checks on a monthly or quarterly cadence, alerts for new issues or threshold breaches, vocabulary drift detection (new unmapped codes, deprecated terms), pipeline freshness and SLA monitoring, model and cohort stability signals where applicable, and executive reporting dashboards. It’s designed to catch degradation before it becomes visible in your dashboards or reports.
Not sure where to start? Most organizations begin with Phase 1 to establish maturity, data-quality risk, and a prioritized roadmap — then modernize only where findings justify it.
Book a discovery call